IJCM  Vol.7 No.1 , January 2016
Hemoglobin Subunit Beta Gene Polymorphism rs33949930 T>C and Risk of Sickle Cell Disease—A Case Control Study from Tabuk (Northwestern Part of Saudi Arabia)
Abstract: Background: Sickle cell disease and sickle cell trait are common erythrocyte disorders that are most often caused by a point mutation (rs334, designated HbS) in the hemoglobin beta gene (HBB); however of this fact, there is extreme variability in occurrence and clinical presentation of sickle cell disease which may be explained by some other genetic changes associated with the gene. In the present study we examined the association between HBB gene polymorphism rs33949930 T>C in the occurrence of sickle cell disease in Saudi Arabia population. Materials and Methods: A case control study of 100 sickle cell disease patients and 100 healthy controls from Tabuk, Saudi Arabia. HBB gene rs33949930 T>C polymorphism was analyzed using Allele specific polymerase chain reaction technique. Results: It was observed that the genotype percentages TT, TC and CC among the patients with sickle cell disease were 63.0%, 35.0% and 2.0% and healthy controls were 68.0%, 27.0% and 5.0% respectively. Allele frequency for T allele was observed to be fT = 0.20 and fT = 0.19, where as for C allele was fC = 0.80 and fC = 0.81 among cases and controls respectively (p = 0.29). Compared to the TT genotype, the odds ratio of 1.4 (95% CI 0.76 - 2.57), risk ratio of 1.2 (95% CI 0.86 - 1.65) and risk difference of 8.4 (-6.66 - 23.38) for heterozygous genotype of HBB rs33949930 T>C was observed in relation to sickle cell disease. In addition, some difference in the laboratory values was observed among sickle cell disease patients with the different variants of HBB gene rs33949930 T>C polymorphism, especially the carriers of heterozygous TC genotype; however, the difference doesn’t reach to statically significant number. Conclusion: Present study suggested that there was not any significant association between HBB gene rs33949930 T>C polymorphism and occurrence of sickle cell disease. However, the heterozygous TC genotype of the polymorphism showed some higher ratios among cases as compared to healthy control group.
Cite this paper: Mir, R. , Sharaf, F. and FM, A. (2016) Hemoglobin Subunit Beta Gene Polymorphism rs33949930 T>C and Risk of Sickle Cell Disease—A Case Control Study from Tabuk (Northwestern Part of Saudi Arabia). International Journal of Clinical Medicine, 7, 25-31. doi: 10.4236/ijcm.2016.71004.

[1]   Weatherall, D.J. and Clegg, J.B. (2001) Inherited Haemoglobin Disorders: An Increasing Global Health Problem. Bulletin of the World Health Organization, 79, 704-712.

[2]   Adewoyin, A.S. (2015) Management of Sickle Cell Disease: A Review for Physician Education in Nigeria (Sub-Saharan Africa). Anemia, 2015, Article ID: 791498.


[4]   Lehmann, H., Maranjian, G. and Mourant, A.E. (1963) Distribution of Sickle-Cell Hemoglobin in Saudi Arabia. Nature, 198, 492-493.

[5]   Al-Qurashi, M.M., El-Mouzan, M.I., Al-Herbish, A.S., Al-Salloum, A.A. and Al-Omar, A.A. (2008) The Prevalence of Sickle Cell Disease in Saudi Children and Adolescents. A Community-Based Survey. Saudi Medical Journal, 29, 1480-1483.

[6]   AlHamdan, N.A., AlMazrou, Y.Y., Al Swaidi, F.M. and Choudhry, A.J. (2007) Premarital Screening for Thalassemia and Sickle Cell Disease in Saudi Arabia. Genetics in Medicine, 9, 372-377.

[7]   el-Hazmi, M.A. and Warsy, A.S. (1999) Appraisal of Sickle-Cell and Thalassaemia Genes in Saudi Arabia. Eastern Mediterranean Health Journal, 5, 1147-1153.

[8]   el-Hazmi, M.A. (1992) Clinical and Haematological Diversity of Sickle Cell Disease in Saudi Children. Journal of Tropical Pediatrics, 38, 106-112.

[9]   Steinberg, M.H. (2005) Predicting Clinical Severity in Sickle Cell Anaemia. British Journal of Haematology, 129, 465-481.

[10]   Pule, G.D., Ngo Bitoungui, V.J., Chetcha Chemegni, B., Kengne, A.P., Antonarakis, S. and Wonkam, A. (2015) Association between Variants at BCL11A Erythroid-Specific Enhancer and Fetal Hemoglobin Levels among Sickle Cell Disease Patients in Cameroon: Implications for Future Therapeutic Interventions. OMICS, 19, 627-631.

[11]   Wonkam, A., Ngo Bitoungui, V.J. and Ngogang, J. (2015) Perspectives in Genetics and Sickle Cell Disease Prevention in Africa: Beyond the Preliminary Data from Cameroon. Public Health Genomics, 18, 237-241.

[12]   Mtatiro, S.N., Mgaya, J., Singh, T., Mariki, H., Rooks, H., Soka, D., Mmbando, B., Thein, S.L., Barrett, J.C., Makani, J., Cox, S.E. and Menzel, S. (2015) Genetic Association of Fetal-Hemoglobin Levels in Individuals with Sickle Cell Disease in Tanzania Maps to Conserved Regulatory Elements within the MYB Core Enhancer. BMC Medical Genetics, 16, 4.

[13]   Bhanushali, A.A., Patra, P.K., Pradhan, S., Khanka, S.S., Singh, S. and Das, B.R. (2015) Genetics of Fetal Hemoglobin in Tribal Indian Patients with Sickle Cell Anemia. Translational Research, 165, 696-703.

[14]   Shooter, C., Rooks, H., Thein, S.L. and Clark, B. (2015) Next Generation Sequencing Identifies a Novel Rearrangement in the HBB Cluster Permitting to-the-Base Characterization. Human Mutation, 36, 142-150.

[15]   Chen, M., Tan, A.S., Cheah, F.S., Saw, E.E. and Chong, S.S. (2015) Identification of Novel Microsatellite Markers <1 Mb from the HBB Gene and Development of a Single-Tube Pentadecaplex PCR Panel of Highly Polymorphic Markers for Preimplantation Geneticdiagnosis of Beta-Thalassemia. Electrophoresis.

[16]   Wonkam, A., Makani, J., Ofori-Aquah, S., Nnodu, O.E., Treadwell, M., Royal, C. and Ohene-Frempong, K., Members of the H3Africa Consortium (2015) Sickle Cell Disease and H3Africa: Enhancing Genomic Research on Cardiovascular Diseases in African Patients. Cardiovascular Journal of Africa, 26, S50-S55.

[17]   Noble, J.A., Duru, K.C., Guindo, A., Yi, L., Imumorin, I.G., Diallo, D.A. and Thomas, B.N. (2015) Interethnic Diversity of the CD209 (rs4804803) Gene Promoter Polymorphism in African but Not American Sickle Cell Disease. PeerJ, 3, e799.

[18]   Kamel, K., El-Najjar, A., Webber, B.B., Chen, S.S., Wilson, J.B., Kutlar, A. and Huisman, T.H.J. (1985) Hb Doha or Beta(X-N-Met-1(NA1)val-to-glu); a New Beta-Chain Abnormal Hemog-lobin Observed in a Qatari Female. Biochimica et Biophysica Acta, 831, 257-260.

[19]   Steinberg, M.H. and Adewoye, A.H. (2006) Modifier Genes and Sickle Cell Anemia. Current Opinion in Hematology, 13, 131-136.

[20]   Adams, G.T., Snieder, H., McKie, V.C., Clair, B., Brambilla, D., Adams, R.J., et al. (2003) Genetic Risk Factors for Cerebrovascular Disease in Children with Sickle Cell Disease: Design of a Case-Control Association Study and Genome Wide Screen. BMC Medical Genetics, 4, 6.

[21]   Kamel, K., El-Najjar, A., Webberc, B.B., Chen, S.S., Wilson, J.B., Kutlar, A. and Huisman, T.H.J. (2002) Hb Doha or α2β2[X-N-Met-1-(NA1)Val → Glu]; a New β-Chain Abnormal Hemoglobin Observed in a Qatari Female. Biochimica et Biophysica Acta (BBA)—Protein Structure and Molecular Enzymology, 1597, 173-344.

[22]   Fisher, C., Hanslip, J., Green, B.N., Gupta, V., Old, J.M. and Rees, D.C. (2000) Hb Watford (Beta-1(NA1)val-to-gly): A New, Clinically Silent Hemoglobin Variant in Linkage with a New Neutral Mutation (Cap+36(G-A)). Hemoglobin, 24, 347-353.